Femasys Inc. (FEMY) Stock Analysis
A live, multi-source view of Femasys Inc. (FEMY): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Femasys Inc.
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It also provides FemBloc, a non-surgical female permanent birth control solution. The company offers its products to gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Sector: Healthcare · Industry: Medical Instruments & Supplies · United States · 51 employees · femasys.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Femasys Inc. (FEMY) had a market capitalization of $25.0M (forward -1.4) and a beta of -2.07; the shares traded in a 52-week range of $2.02 – $22.20 (-60.3% over the year).
- Market cap
- $25.0M
- Enterprise value
- $28.3M
- Forward P/E
- -1.4
- Price / book
- 2.24
- EPS (trailing)
- $-2.66
- EPS (forward)
- $-2.13
- Payout ratio
- 0.0%
- 52-week range
- $2.02 – $22.20
- 52-week change
- -60.3%
- Beta
- -2.07
- Average volume
- 731,893
- Shares outstanding
- 8.4M
- Short % of float
- 5.28%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Femasys Inc. (FEMY) last closed at $2.83 (the last completed close before that scan).
Technicals at the scan: RSI 47 (neutral territory), price +1.4% versus its 20-day average, 20-day versus 50-day average spread -11.1%, MACD histogram 0.03.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 92/100.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of FEMY; corporate insiders filed 5 buys and 0 sells (5 distinct filers, latest disclosure 2026-08-11). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Jeffrey Gerald Mifek (1B/0S), Kathy Lee-Sepsick (1B/0S), John Charles Canning (1B/0S), Jeremy Alexander Sipos (1B/0S), Dov Elefant (1B/0S). Who is trading what
RapidTradeView pick record
FEMY has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Femasys Inc. (FEMY) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell FEMY.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.